Literature DB >> 35224497

Insights into the modular design of kinase inhibitors and application to Abl and Axl.

Sameer Phadke1, Lluis Lopez-Barcons2, Nathalie Vandecan1, Zhifen Wu2, Taylor K Johnson1, Eric J Lachacz1, Sofia D Merajver2, Matthew B Soellner1.   

Abstract

Scaffold hopping is a common strategy for generating kinase inhibitors that bind to the DFG-out inactive conformation. Small structural differences in inhibitor scaffolds can have significant effects on potency and selectivity across the kinome, however, these effects are often not studied in detail. Herein, we outline a design strategy to generate an array of DFG-out conformation inhibitors with three different hinge-binders and two DFG-pocket groups. We studied inhibitor selectivity across a large segment of the kinome and elucidated binding preferences that can be used in scaffold hopping campaigns. Using these analyses, we identified two selective inhibitors that display low nanomolar potency against Axl or wild-type and clinically relevant mutants of Abl. This journal is © The Royal Society of Chemistry.

Entities:  

Year:  2021        PMID: 35224497      PMCID: PMC8792823          DOI: 10.1039/d1md00296a

Source DB:  PubMed          Journal:  RSC Med Chem        ISSN: 2632-8682


  8 in total

1.  Comprehensive analysis of kinase inhibitor selectivity.

Authors:  Mindy I Davis; Jeremy P Hunt; Sanna Herrgard; Pietro Ciceri; Lisa M Wodicka; Gabriel Pallares; Michael Hocker; Daniel K Treiber; Patrick P Zarrinkar
Journal:  Nat Biotechnol       Date:  2011-10-30       Impact factor: 54.908

2.  Comprehensive characterization of the Published Kinase Inhibitor Set.

Authors:  Jonathan M Elkins; Vita Fedele; Marta Szklarz; Kamal R Abdul Azeez; Eidarus Salah; Jowita Mikolajczyk; Sergei Romanov; Nikolai Sepetov; Xi-Ping Huang; Bryan L Roth; Ayman Al Haj Zen; Denis Fourches; Eugene Muratov; Alex Tropsha; Joel Morris; Beverly A Teicher; Mark Kunkel; Eric Polley; Karen E Lackey; Francis L Atkinson; John P Overington; Paul Bamborough; Susanne Müller; Daniel J Price; Timothy M Willson; David H Drewry; Stefan Knapp; William J Zuercher
Journal:  Nat Biotechnol       Date:  2015-10-26       Impact factor: 54.908

3.  Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036.

Authors:  Wayne W Chan; Scott C Wise; Michael D Kaufman; Yu Mi Ahn; Carol L Ensinger; Torsten Haack; Molly M Hood; Jennifer Jones; John W Lord; Wei Ping Lu; David Miller; William C Patt; Bryan D Smith; Peter A Petillo; Thomas J Rutkoski; Hanumaiah Telikepalli; Lakshminarayana Vogeti; Tony Yao; Lawrence Chun; Robin Clark; Peter Evangelista; L Cristina Gavrilescu; Katherine Lazarides; Virginia M Zaleskas; Lance J Stewart; Richard A Van Etten; Daniel L Flynn
Journal:  Cancer Cell       Date:  2011-04-12       Impact factor: 31.743

4.  Conformation-Selective Analogues of Dasatinib Reveal Insight into Kinase Inhibitor Binding and Selectivity.

Authors:  Frank E Kwarcinski; Kristoffer R Brandvold; Sameer Phadke; Omar M Beleh; Taylor K Johnson; Jennifer L Meagher; Markus A Seeliger; Jeanne A Stuckey; Matthew B Soellner
Journal:  ACS Chem Biol       Date:  2016-03-01       Impact factor: 5.100

5.  Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance.

Authors:  Tianjun Zhou; Lois Commodore; Wei-Sheng Huang; Yihan Wang; Mathew Thomas; Jeff Keats; Qihong Xu; Victor M Rivera; William C Shakespeare; Tim Clackson; David C Dalgarno; Xiaotian Zhu
Journal:  Chem Biol Drug Des       Date:  2010-11-30       Impact factor: 2.817

6.  Coral: Clear and Customizable Visualization of Human Kinome Data.

Authors:  Kathleen S Metz; Erika M Deoudes; Matthew E Berginski; Ivan Jimenez-Ruiz; Bulent Arman Aksoy; Jeff Hammerbacher; Shawn M Gomez; Douglas H Phanstiel
Journal:  Cell Syst       Date:  2018-08-29       Impact factor: 10.304

7.  Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant.

Authors:  Wei-Sheng Huang; Chester A Metcalf; Raji Sundaramoorthi; Yihan Wang; Dong Zou; R Mathew Thomas; Xiaotian Zhu; Lisi Cai; David Wen; Shuangying Liu; Jan Romero; Jiwei Qi; Ingrid Chen; Geetha Banda; Scott P Lentini; Sasmita Das; Qihong Xu; Jeff Keats; Frank Wang; Scott Wardwell; Yaoyu Ning; Joseph T Snodgrass; Marc I Broudy; Karin Russian; Tianjun Zhou; Lois Commodore; Narayana I Narasimhan; Qurish K Mohemmad; John Iuliucci; Victor M Rivera; David C Dalgarno; Tomi K Sawyer; Tim Clackson; William C Shakespeare
Journal:  J Med Chem       Date:  2010-06-24       Impact factor: 7.446

Review 8.  Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery?

Authors:  Zheng Zhao; Hong Wu; Li Wang; Yi Liu; Stefan Knapp; Qingsong Liu; Nathanael S Gray
Journal:  ACS Chem Biol       Date:  2014-04-29       Impact factor: 5.100

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.